Cargando…
The Quinazoline Otaplimastat (SP-8203) Reduces the Hemorrhagic Transformation and Mortality Aggravated after Delayed rtPA-Induced Thrombolysis in Cerebral Ischemia
Acute ischemic stroke is the leading cause of morbidity and mortality worldwide. Recombinant tissue plasminogen activator (rtPA) is the only agent clinically approved by FDA for patients with acute ischemic stroke. However, delayed treatment of rtPA (e.g., more than 3 h after stroke onset) exacerbat...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8835804/ https://www.ncbi.nlm.nih.gov/pubmed/35163322 http://dx.doi.org/10.3390/ijms23031403 |
_version_ | 1784649522506366976 |
---|---|
author | Song, Hwa Young Chung, Jee-In Jalin, Angela Melinda Anthony Ju, Chung Pahk, Kisoo Joung, Chanmin Lee, Sekwang Jin, Sejong Kim, Byoung Soo Lee, Ki Sung Ryu, Jei-Man Kim, Won-Ki |
author_facet | Song, Hwa Young Chung, Jee-In Jalin, Angela Melinda Anthony Ju, Chung Pahk, Kisoo Joung, Chanmin Lee, Sekwang Jin, Sejong Kim, Byoung Soo Lee, Ki Sung Ryu, Jei-Man Kim, Won-Ki |
author_sort | Song, Hwa Young |
collection | PubMed |
description | Acute ischemic stroke is the leading cause of morbidity and mortality worldwide. Recombinant tissue plasminogen activator (rtPA) is the only agent clinically approved by FDA for patients with acute ischemic stroke. However, delayed treatment of rtPA (e.g., more than 3 h after stroke onset) exacerbates ischemic brain damage by causing intracerebral hemorrhage and increasing neurotoxicity. In the present study, we investigated whether the neuroprotant otaplimastat reduced delayed rtPA treatment-evoked neurotoxicity in male Sprague Dawley rats subjected to embolic middle cerebral artery occlusion (eMCAO). Otaplimastat reduced cerebral infarct size and edema and improved neurobehavioral deficits. In particular, otaplimastat markedly reduced intracerebral hemorrhagic transformation and mortality triggered by delayed rtPA treatment, consequently extending the therapeutic time window of rtPA. We further found that ischemia-evoked extracellular matrix metalloproteases (MMPs) expression was closely correlated with cerebral hemorrhagic transformation and brain damage. In ischemic conditions, delayed rtPA treatment further increased brain injury via synergistic expression of MMPs in vascular endothelial cells. In oxygen-glucose-deprived endothelial cells, otaplimastat suppressed the activity rather than protein expression of MMPs by restoring the level of tissue inhibitor of metalloproteinase (TIMP) suppressed in ischemia, and consequently reduced vascular permeation. This paper shows that otaplimastat under clinical trials is a new drug which can inhibit stroke on its own and extend the therapeutic time window of rtPA, especially when administered in combination with rtPA. |
format | Online Article Text |
id | pubmed-8835804 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88358042022-02-12 The Quinazoline Otaplimastat (SP-8203) Reduces the Hemorrhagic Transformation and Mortality Aggravated after Delayed rtPA-Induced Thrombolysis in Cerebral Ischemia Song, Hwa Young Chung, Jee-In Jalin, Angela Melinda Anthony Ju, Chung Pahk, Kisoo Joung, Chanmin Lee, Sekwang Jin, Sejong Kim, Byoung Soo Lee, Ki Sung Ryu, Jei-Man Kim, Won-Ki Int J Mol Sci Article Acute ischemic stroke is the leading cause of morbidity and mortality worldwide. Recombinant tissue plasminogen activator (rtPA) is the only agent clinically approved by FDA for patients with acute ischemic stroke. However, delayed treatment of rtPA (e.g., more than 3 h after stroke onset) exacerbates ischemic brain damage by causing intracerebral hemorrhage and increasing neurotoxicity. In the present study, we investigated whether the neuroprotant otaplimastat reduced delayed rtPA treatment-evoked neurotoxicity in male Sprague Dawley rats subjected to embolic middle cerebral artery occlusion (eMCAO). Otaplimastat reduced cerebral infarct size and edema and improved neurobehavioral deficits. In particular, otaplimastat markedly reduced intracerebral hemorrhagic transformation and mortality triggered by delayed rtPA treatment, consequently extending the therapeutic time window of rtPA. We further found that ischemia-evoked extracellular matrix metalloproteases (MMPs) expression was closely correlated with cerebral hemorrhagic transformation and brain damage. In ischemic conditions, delayed rtPA treatment further increased brain injury via synergistic expression of MMPs in vascular endothelial cells. In oxygen-glucose-deprived endothelial cells, otaplimastat suppressed the activity rather than protein expression of MMPs by restoring the level of tissue inhibitor of metalloproteinase (TIMP) suppressed in ischemia, and consequently reduced vascular permeation. This paper shows that otaplimastat under clinical trials is a new drug which can inhibit stroke on its own and extend the therapeutic time window of rtPA, especially when administered in combination with rtPA. MDPI 2022-01-26 /pmc/articles/PMC8835804/ /pubmed/35163322 http://dx.doi.org/10.3390/ijms23031403 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Song, Hwa Young Chung, Jee-In Jalin, Angela Melinda Anthony Ju, Chung Pahk, Kisoo Joung, Chanmin Lee, Sekwang Jin, Sejong Kim, Byoung Soo Lee, Ki Sung Ryu, Jei-Man Kim, Won-Ki The Quinazoline Otaplimastat (SP-8203) Reduces the Hemorrhagic Transformation and Mortality Aggravated after Delayed rtPA-Induced Thrombolysis in Cerebral Ischemia |
title | The Quinazoline Otaplimastat (SP-8203) Reduces the Hemorrhagic Transformation and Mortality Aggravated after Delayed rtPA-Induced Thrombolysis in Cerebral Ischemia |
title_full | The Quinazoline Otaplimastat (SP-8203) Reduces the Hemorrhagic Transformation and Mortality Aggravated after Delayed rtPA-Induced Thrombolysis in Cerebral Ischemia |
title_fullStr | The Quinazoline Otaplimastat (SP-8203) Reduces the Hemorrhagic Transformation and Mortality Aggravated after Delayed rtPA-Induced Thrombolysis in Cerebral Ischemia |
title_full_unstemmed | The Quinazoline Otaplimastat (SP-8203) Reduces the Hemorrhagic Transformation and Mortality Aggravated after Delayed rtPA-Induced Thrombolysis in Cerebral Ischemia |
title_short | The Quinazoline Otaplimastat (SP-8203) Reduces the Hemorrhagic Transformation and Mortality Aggravated after Delayed rtPA-Induced Thrombolysis in Cerebral Ischemia |
title_sort | quinazoline otaplimastat (sp-8203) reduces the hemorrhagic transformation and mortality aggravated after delayed rtpa-induced thrombolysis in cerebral ischemia |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8835804/ https://www.ncbi.nlm.nih.gov/pubmed/35163322 http://dx.doi.org/10.3390/ijms23031403 |
work_keys_str_mv | AT songhwayoung thequinazolineotaplimastatsp8203reducesthehemorrhagictransformationandmortalityaggravatedafterdelayedrtpainducedthrombolysisincerebralischemia AT chungjeein thequinazolineotaplimastatsp8203reducesthehemorrhagictransformationandmortalityaggravatedafterdelayedrtpainducedthrombolysisincerebralischemia AT jalinangelamelindaanthony thequinazolineotaplimastatsp8203reducesthehemorrhagictransformationandmortalityaggravatedafterdelayedrtpainducedthrombolysisincerebralischemia AT juchung thequinazolineotaplimastatsp8203reducesthehemorrhagictransformationandmortalityaggravatedafterdelayedrtpainducedthrombolysisincerebralischemia AT pahkkisoo thequinazolineotaplimastatsp8203reducesthehemorrhagictransformationandmortalityaggravatedafterdelayedrtpainducedthrombolysisincerebralischemia AT joungchanmin thequinazolineotaplimastatsp8203reducesthehemorrhagictransformationandmortalityaggravatedafterdelayedrtpainducedthrombolysisincerebralischemia AT leesekwang thequinazolineotaplimastatsp8203reducesthehemorrhagictransformationandmortalityaggravatedafterdelayedrtpainducedthrombolysisincerebralischemia AT jinsejong thequinazolineotaplimastatsp8203reducesthehemorrhagictransformationandmortalityaggravatedafterdelayedrtpainducedthrombolysisincerebralischemia AT kimbyoungsoo thequinazolineotaplimastatsp8203reducesthehemorrhagictransformationandmortalityaggravatedafterdelayedrtpainducedthrombolysisincerebralischemia AT leekisung thequinazolineotaplimastatsp8203reducesthehemorrhagictransformationandmortalityaggravatedafterdelayedrtpainducedthrombolysisincerebralischemia AT ryujeiman thequinazolineotaplimastatsp8203reducesthehemorrhagictransformationandmortalityaggravatedafterdelayedrtpainducedthrombolysisincerebralischemia AT kimwonki thequinazolineotaplimastatsp8203reducesthehemorrhagictransformationandmortalityaggravatedafterdelayedrtpainducedthrombolysisincerebralischemia AT songhwayoung quinazolineotaplimastatsp8203reducesthehemorrhagictransformationandmortalityaggravatedafterdelayedrtpainducedthrombolysisincerebralischemia AT chungjeein quinazolineotaplimastatsp8203reducesthehemorrhagictransformationandmortalityaggravatedafterdelayedrtpainducedthrombolysisincerebralischemia AT jalinangelamelindaanthony quinazolineotaplimastatsp8203reducesthehemorrhagictransformationandmortalityaggravatedafterdelayedrtpainducedthrombolysisincerebralischemia AT juchung quinazolineotaplimastatsp8203reducesthehemorrhagictransformationandmortalityaggravatedafterdelayedrtpainducedthrombolysisincerebralischemia AT pahkkisoo quinazolineotaplimastatsp8203reducesthehemorrhagictransformationandmortalityaggravatedafterdelayedrtpainducedthrombolysisincerebralischemia AT joungchanmin quinazolineotaplimastatsp8203reducesthehemorrhagictransformationandmortalityaggravatedafterdelayedrtpainducedthrombolysisincerebralischemia AT leesekwang quinazolineotaplimastatsp8203reducesthehemorrhagictransformationandmortalityaggravatedafterdelayedrtpainducedthrombolysisincerebralischemia AT jinsejong quinazolineotaplimastatsp8203reducesthehemorrhagictransformationandmortalityaggravatedafterdelayedrtpainducedthrombolysisincerebralischemia AT kimbyoungsoo quinazolineotaplimastatsp8203reducesthehemorrhagictransformationandmortalityaggravatedafterdelayedrtpainducedthrombolysisincerebralischemia AT leekisung quinazolineotaplimastatsp8203reducesthehemorrhagictransformationandmortalityaggravatedafterdelayedrtpainducedthrombolysisincerebralischemia AT ryujeiman quinazolineotaplimastatsp8203reducesthehemorrhagictransformationandmortalityaggravatedafterdelayedrtpainducedthrombolysisincerebralischemia AT kimwonki quinazolineotaplimastatsp8203reducesthehemorrhagictransformationandmortalityaggravatedafterdelayedrtpainducedthrombolysisincerebralischemia |